CMMB - Chemomab Therapeutics Ltd.

1.88
0.050   2.660%

Share volume: 51,557
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$1.83
0.05
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
6%
Profitability 0%
Dept financing 6%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
4.85%
1 Month
16.05%
3 Months
-31.39%
6 Months
-38.26%
1 Year
44.62%
2 Year
142.58%
Key data
Stock price
$1.88
P/E Ratio 
0.00
DAY RANGE
$1.77 - $1.91
EPS 
$0.04
52 WEEK RANGE
$0.83 - $3.86
52 WEEK CHANGE
$44.62
MARKET CAP 
1.127 M
YIELD 
N/A
SHARES OUTSTANDING 
14.219 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
1.16
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$108,101
AVERAGE 30 VOLUME 
$112,575
Company detail
CEO: Dale R. Pfost
Region: US
Website: chemomab.com
Employees: 20
IPO year: 2019
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Chemomab Therapeutics Ltd. discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24.

Recent news